2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatients
2004
Sleep duration and risk of diabetes in middle-aged and older men: prospective results from the Massachusetts male aging study
Araujo A, Yaggi H, McKinlay J. Sleep duration and risk of diabetes in middle-aged and older men: prospective results from the Massachusetts male aging study. Annals Of Epidemiology 2004, 14: 598. DOI: 10.1016/j.annepidem.2004.07.019.Peer-Reviewed Original ResearchRisk of diabetesDevelopment of diabetesSleep durationRelative riskHours sleepClinical diabetesRisk factorsIncidence ratePopulation-based prospective cohortMassachusetts Male Aging StudyEstimated relative risksSleep duration categoriesIndependent risk factorYear of diagnosisImpaired glucose metabolismCases of diabetesSelf-reported diagnosisShort sleep durationEnd of studyLong sleep durationSelf-reported average numberSelf-rated healthIncident diabetesCohort studyEffect of age